Pharma BD Deal Intelligence

Insud Pharma / Agile Therapeutics, Inc.

2024 · Acquisition/Merger · $45M · Pending

Agile Therapeutics entered a definitive merger agreement to be acquired by Spanish pharmaceutical group Insud Pharma, through its US affiliate Exeltis, for USD 1.52 per share in cash, implying an enterprise value of approximately USD 45 million and a large premium to the prior close. The transaction combines Agile's women's health portfolio, anchored by the Twirla transdermal contraceptive patch, with Exeltis's established US operations; the parties stated the deal was expected to close in the third quarter of 2024 subject to shareholder approval.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2029 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2024 deals